Nanoparticle-Mediated Co-Delivery of Notch-1 Antibodies and ABT-737 as a Potent Treatment Strategy for Triple-Negative Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) accounts for nearly one-quarter of all breast cancer cases, but effective targeted therapies for this disease remain elusive because TNBC cells lack expression of the three most common receptors seen on other subtypes of breast cancer. Here, we exploit TNBC cells’ overexpression of Notch-1 receptors and Bcl-2 anti-apoptotic proteins to provide an effective targeted therapy. Prior studies have shown that the small molecule drug ABT-737, which inhibits Bcl-2 to reinstate apoptotic signaling, is a promising candidate for TNBC therapy. However, ABT-737 is poorly soluble in aqueous conditions, and its orally bioavailable derivative causes severe thrombocytopenia. To enable targeted delivery of ABT-737 to TNBC and enhance its therapeutic efficacy, we encapsulated the drug in poly­(lactic-co-glycolic acid) nanoparticles (NPs) that were functionalized with Notch-1 antibodies to produce N1-ABT-NPs. The antibodies in this NP platform enable both TNBC cell-specific binding and suppression of Notch signaling within TNBC cells by locking the Notch-1 receptors in a ligand unresponsive state. This Notch inhibition potentiates the effect of ABT-737 by up-regulating Noxa, resulting in effective killing of TNBC cells. We present the results of in vitro studies that demonstrate N1-ABT-NPs can preferentially bind TNBC cells versus noncancerous breast epithelial cells to effectively regulate Bcl-2 and Notch signaling to induce cell death. Further, we show that N1-ABT-NPs can accumulate in subcutaneous TNBC xenograft tumors in mice following systemic administration to reduce tumor burden and extend animal survival. Together, these findings demonstrate that NP-mediated co-delivery of Notch-1 antibodies and ABT-737 is a potent treatment strategy for TNBC that may improve patient outcomes with further development and implementation.

The Notch Pathway: A Link Between COVID-19 Pathophysiology and Its Cardiovascular Complications

“…Alternatives include Notch-specific antibodies and decoys. Antibodies allow blockade of individual Notch components, thus are not associated with complications seen with the pan inhibitors (156)(157)(158). Notch decoys also selectively block Notch receptors by a unique mechanism that involves mimicking the Notch extracellular domain of a specific Notch ligand or receptor (159,160…”

Engineering precision nanoparticles for drug delivery

“…Overall, polymeric NPs are ideal candidates for drug delivery because they are biodegradable, water soluble, biocompatible, biomimetic and stable during storage. Their surfaces can be easily modified for additional targeting 49 — allowing them to deliver drugs, proteins and genetic material to targeted tissues, which makes them useful in cancer medicine, gene therapy and diagnostics. However, disadvantages of polymeric NPs include an increased risk of particle aggregation and toxicity.…”

Patient‐Derived Prostate Cancer Explants: A Clinically Relevant Model to Assess siRNA‐Based Nanomedicines

“…[ 7 ] Efficacy testing of novel nanomedicine formulations are commonly conducted in vitro and in vivo murine models derived from immortalized human cell lines. [ 8 ] However, their translation very rarely progresses towards clinical evaluation using these preclinical models, which has forced researchers to develop and explore more relevant models. While the underlying issues for the failure of clinical translation are multifactorial, the interspecies differences between murine and humans, and the absence of the complex tumor microenvironment, including the immune component, are likely contributors.…”